AC Immune Announces Upcoming Industry Symposium on Parkinson's Disease and Presentation at AD/PD(TM) 2026
MWN-AI** Summary
AC Immune SA (NASDAQ: ACIU), a biopharmaceutical leader focused on neurodegenerative diseases, is set to host an industry symposium on Parkinson's disease, emphasizing precision prevention strategies informed by Alzheimer's research. This event will occur at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2026) in Copenhagen, Denmark, from March 17-21, 2026.
The symposium, titled “From Treatment to Prevention in Parkinson’s Disease,” will take place on March 18, 2026, and feature key presentations from renowned experts. Andrea Pfeifer, CEO of AC Immune, will provide opening and closing remarks. Other notable speakers include Prof. Catherine Mummery, who will discuss insights from Alzheimer’s treatments, as well as Werner Poewe and Prof. Klaus Gerwert, who will focus on the pathophysiology and biomarker measurement of ?-synuclein in Parkinson's disease. Günther Staffler will present interim results from the Phase 2 VacSYn trial of ACI-7104.056, while Francesca Capotosti will discuss targeting ?-synuclein with Morphomer small molecules.
Additionally, AC Immune will present its innovative TDP-43 PET-tracer, ACI-19626, on March 19, 2026, highlighting its potential as a biomarker for neurodegeneration.
AC Immune is renowned for its pioneering work in developing precision therapeutics, underpinned by its SupraAntigen® and Morphomer® technology platforms. With a strong commitment to advancing treatments for Alzheimer’s and Parkinson’s diseases, the company has established significant partnerships, generating over $4.5 billion in potential milestone payments and royalties.
The symposium is an opportunity for industry professionals to engage in crucial discussions about the prevention and treatment of neurodegenerative diseases, and will be available for replay on AC Immune’s website post-event, providing insights into this evolving field.
MWN-AI** Analysis
AC Immune SA (NASDAQ: ACIU) recently announced significant developments at the upcoming AD/PD™ 2026 conference, including an industry symposium focused on innovative approaches to Parkinson's disease and the unveiling of ACI-19626, its first-in-class TDP-43 PET-tracer. These events underscore AC Immune's commitment to being a leader in precision therapeutics for neurodegenerative diseases.
Investors should note that the Precision Prevention approach highlighted by AC Immune aligns with growing trends in proactive healthcare, particularly in the neurodegenerative space. This shift signifies a potential market realignment favoring companies that integrate preventive strategies into their pipelines. The focus on TDP-43, a protein implicated in both Alzheimer's and Parkinson's diseases, could broaden the applicability and impact of AC Immune's technologies, enhancing its market positioning.
As the industry converges on early intervention and diagnostic capabilities, the successful presentation of ACI-19626 may attract significant attention from investors seeking to capitalize on innovative diagnostics in neurodegeneration. The potential for partnerships and collaborations with pharmaceutical giants could further bolster AC Immune’s financial outlook, given its history of securing substantial non-dilutive funding.
Moreover, the speakers and the breadth of topics to be discussed at the symposium reflect the company’s robust research foundation and connections within the scientific community. These factors can instill confidence in investors regarding AC Immune's long-term growth trajectory.
In summary, AC Immune's strategic focus on preventive neurodegenerative therapies and diagnostics positions it favorably in the biopharmaceutical landscape. Investors should consider maintaining or increasing their positions in ACIU as the implications of these innovations unfold, reinforcing the stock's potential for significant upside in the evolving therapeutic arena.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
AC Immune Announces Upcoming Industry Symposium on Parkinson’s Disease and Presentation at AD/PD™ 2026
- AC Immune to host symposium highlighting Precision Prevention approach to Parkinson's disease
- Presentation at International Conference on Alzheimer’s and Parkinson’s Disease (AD/PD™ 2026) showcases potential of first-in-class TDP-43 PET-tracer ACI-19626
Lausanne, Switzerland, March 5, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced it will host an industry symposium on how a precision prevention approach to Parkinson’s disease may now be within reach, based on lessons from Alzheimer’s disease.
AC Immune will also present its first-in-class TDP-43 PET-tracer on ACI-19626 at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2026) taking place in Copenhagen, Denmark, on March 17-21, 2026.
Industry Symposium: From Treatment to Prevention in Parkinson’s Disease
Session Date/Time: Wednesday, March 18, 2026, 8:40 – 10:40 am CET
Location: Hall A1
- Opening and Closing Remarks: Andrea Pfeifer, Ph.D., CEO of AC Immune
- Shifting treatment to prevention: lessons learned from Alzheimer’s disease
Presenter: Prof. Catherine Mummery (University College London)
Time: 8:45 – 9:00 am CET
- Targeting ?-synuclein in Parkinson’s disease: pathophysiology and supporting evidence
Presenter: Werner Poewe, M.D. (Medical University of Innsbruck)
Time: 9:00 – 9:25 am CET
- Misfolding of ?-synuclein as fluid biomarker measured with the iRS platform of betaSENSE
Presenter: Prof. Klaus Gerwert (Centre for Protein Diagnostics at Ruhr University Bochum)
Time: 9:25 – 9:40 am CET
- Stabilizing the progression of Parkinson’s disease with active immunotherapy: Interim results of the Phase 2 VacSYn trial of ACI-7104.056
Presenter: Günther Staffler, Ph.D. (AC Immune)
Time: 9:40 – 10:05 am CET
- Intracellular targeting of ?-synuclein with Morphomer small molecules
Presenter: Francesca Capotosti, Ph.D. (AC Immune)
Time: 10:05 – 10:20 am CET
The presentations will be followed by a Q&A session, and a replay of the Industry Symposium will be available on the Events page of AC Immune’s website after the event.
Oral Presentation
- Discovery and initial clinical evaluation of [18f]ACI-19626, a first-in-class TDP-43 PET-tracer
Presenter: Tamara Seredenina, Ph.D. (AC Immune)
Session: Biomarker Pathways Linking Amyloid, Tau, and Neurodegeneration
Location: Hall 180-181
Date/Time: Thursday, March 19, 2026 at 4:50 – 5:05 pm CET
About AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company and a global leader in precision prevention for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen® and Morphomer®, fuel its pipeline of first- and best-in-class assets, which currently features a range of therapeutic and diagnostic programs, including candidates in Phase 2 and Phase 3 development. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies, resulting in substantial non-dilutive funding to advance its proprietary programs and >$4.5 billion in potential milestone payments plus royalties.
SupraAntigen® is a registered trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP, RU, SG and USA. Morphomer® is a registered trademark of AC Immune SA in CA, CN, CH, EU, GB, JP, KR, NO, RU and SG.
The information on our website and any other websites referenced herein is expressly not incorporated by reference into, and does not constitute a part of, this press release.
For further information, please contact:
| SVP, Investor Relations & Corporate Communications Gary Waanders, Ph.D., MBA AC Immune Phone: +41 21 345 91 91 Email: gary.waanders@acimmune.com | |
| International Media Chris Maggos Cohesion Bureau Phone: +41 79 367 6254 Email: chris.maggos@cohesionbureau.com |
Forward looking statements
This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.
Attachment
FAQ**
How does AC Immune SA (NASDAQ: ACIU) plan to leverage lessons learned from Alzheimer's disease in its precision prevention approach to Parkinson's disease at the upcoming symposium?
What specific advancements does the first-in-class TDP-43 PET-tracer ACI-196represent for AC Immune SA (ACIU) in the diagnosis and management of neurodegenerative diseases?
Can you shed light on the interim results of the Phase 2 VacSYn trial of ACI-7104.056 and its implications for AC Immune SA (ACIU)'s approach to stabilizing Parkinson’s disease progression?
In what ways does AC Immune SA (ACIU) envision its Morphomer technology platform enhancing therapeutic options for targeting misfolded proteins in Parkinson’s disease?
**MWN-AI FAQ is based on asking OpenAI questions about AC Immune SA (NASDAQ: ACIU).
NASDAQ: ACIU
ACIU Trading
3.32% G/L:
$2.80 Last:
12,864 Volume:
$2.76 Open:
